Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis-Reference-Cited by-同舟云学术

Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

Published:2022-11-15 Issue:11 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lingscheid Tilman¹^ORCID,Kinzig Martina²,Krüger Anne³,Müller Nils³,Bölke Georg³,Tober-Lau Pinkus¹,Münn Friederike¹,Kriedemann Helene¹,Witzenrath Martin¹⁴,Sander Leif E.¹⁴⁵,Sörgel Fritz²⁶,Kurth Florian¹⁷^ORCID

Affiliation:

1. Department of Infectious Diseases and Respiratory Medicine, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

2. IBMP–Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany

3. Department of Nephrology and Intensive Care, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

4. German Center for Lung Research, DZL, Berlin, Germany

5. Berlin Institute of Health, Berlin, Germany

6. Institute of Pharmacology, West German Heart and Vascular Centre, University of Duisburg-Essen, Essen, Germany

7. Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Hamburg, Germany

Abstract

Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data.

Funder

Berlin Institute of Health

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01229-22

Reference15 articles.

1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19